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Abstract
Background: The prevalence of diabetes is predicted to rise significantly in the coming decades. A recent analysis 
projects that by the year 2030 there will be ~366 million diabetics around the world, leading to an increased demand 
for inexpensive insulin to make this life-saving drug also affordable for resource poor countries.
Results: A synthetic insulin precursor (IP)-encoding gene, codon-optimized for expression in P. pastoris, was cloned in 
frame with the Saccharomyces cerevisiae α-factor secretory signal and integrated into the genome of P. pastoris strain X-
33. The strain was grown to high-cell density in a batch procedure using a defined medium with low salt and high 
glycerol concentrations. Following batch growth, production of IP was carried out at methanol concentrations of 2 g L-
1, which were kept constant throughout the remaining production phase. This robust feeding strategy led to the 
secretion of ~3 gram IP per liter of culture broth (corresponding to almost 4 gram IP per liter of cell-free culture 
supernatant). Using immobilized metal ion affinity chromatography (IMAC) as a novel approach for IP purification, 95% 
of the secreted product was recovered with a purity of 96% from the clarified culture supernatant. Finally, the purified 
IP was trypsin digested, transpeptidated, deprotected and further purified leading to ~1.5 g of 99% pure recombinant 
human insulin per liter of culture broth.
Conclusions: A simple two-phase cultivation process composed of a glycerol batch and a constant methanol fed-
batch phase recently developed for the intracellular production of the Hepatitis B surface antigen was adapted to 
secretory IP production. Compared to the highest previously reported value, this approach resulted in an ~2 fold 
enhancement of IP production using Pichia based expression systems, thus significantly increasing the efficiency of 
insulin manufacture.
Background
Diabetes is a progressive disease characterized by hyperg-
lycemia, resulting from defects in insulin secretion, its
function, or both. The long-term effects of this disease,
for which there is no cure, lead to multiple organ damage
and failure [1]. The World Health Organization estimates
that ~2.9 million deaths are attributable to diabetes every
year [2]. Based on demographic changes, it has been esti-
mated that the number of diabetics around the world,
which was ~171 million at the turn of this century, will
more than double by the year 2030 [3]. This is likely to be
an underestimate given that factors, such as improved life
expectancy and obesity contributing to increased preva-
lence of diabetes, have not been taken into consideration.
Insulin is a 51 amino acid (aa) polypeptide hormone
essential for normal glucose homeostasis and is therefore
useful in treating diabetes. Insulin contains two polypep-
tide chains, A (21 aa) and B (30 aa), with three disulfide
bonds. Two of these interlink the A- and B-chains, while
the third one is an intra A-chain bond [4,5]. Though, ini-
tially, insulin was isolated from porcine pancreas, the
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advent of recombinant DNA technology helped to
address the requirement for insulin more effectively.
However, commensurate with the projected escalation in
the prevalence of diabetes in the coming decades [3],
there will be an increasing demand for insulin. To meet
this, more cost-effective biotechnological strategies for
recombinant insulin production are required.
Insulin was the first recombinant product approved by
the FDA for human application [6,7]. The first expression
systems were based on the separate expression of the A-
and B-chains fused to carrier proteins in two different E.
coli strains [8,9]. Nowadays, human insulin is produced as
recombinant protein, using two major routes. One route
involves the production of an insulin precursor in the
form of inclusion bodies, using E. coli as expression host
with subsequent solubilization and refolding procedures
[10]. The other route involves the utilization of yeast-
based expression systems, leading to the secretion of a
soluble insulin precursor (IP) into the culture superna-
tant [11-13]. Both routes are economically viable. Due to
the extensive experience in large-scale cultivation, Sac-
charomyces cerevisiae became the first yeast-based
expression system for secretory IP production [11,12].
Though S. cerevisiae is still the predominant yeast system
for insulin production, several alternative yeast hosts
have become available in recent years [14-18]. Of these,
the methylotrophic yeast Pichia pastoris has emerged as a
very useful expression host with superior features [18-
21]. In particular, its reliance on integrative vectors, its
strong and tightly regulated methanol-inducible alcohol
oxidase 1 (AOX1) promoter and its capacity to reach very
high cell densities by simple cultivation strategies collec-
tively contribute to stable and high level production of
recombinant proteins.
Several reports have also demonstrated the utility of P.
pastoris for secretory IP production [22-30]. The yields
reported so far vary over a wide range, with the highest
being 1.5 gram IP per liter of culture broth (Table 1).
Thus, P. pastoris has proven its applicability for insulin
production, and, in fact, a comparative study revealed an
equal or even better performance of P. pastoris compared
to S. cerevisiae [22].
For secretory IP production using P. pastoris as host,
the  S. cerevisiae based α-factor pre-pro leader is most
often employed as secretion signal [13]. In general, the
insulin B- and A-chains are joined by a short connecting
peptide linker, which allows tryptic precursor processing
for generation of human insulin [22,25,26,31]. Secretion
yields of the single chain insulin precursors can be
enhanced by adding a charged synthetic spacer peptide in
front of the insulin B-chain segment, which allows more
efficient Kex2 endoprotease processing after the α-factor
pre-pro leader [13,22,32]. After recovery from the culture
broth, IP can be converted enzymatically into human
insulin [26,27,29,33,34].
We recently devised a robust cultivation strategy for
high-level intracellular production of the Hepatitis B sur-
face antigen (HBsAg), using P. pastoris as expression host
[35]. In this procedure, cells were first grown to high-cell
density in a batch process, using a simple defined
medium with low salt and high glycerol concentrations.
After batch growth, induction of high-level product for-
mation was achieved by adding methanol to a final con-
centration of 6 g L-1 and keeping this high concentration
for the remainder of the production phase. In the present
work, we have adapted this strategy to secretory IP pro-
duction. Further, we also present a novel purification pro-
cedure, based on the metal binding affinity of IP and,
finally, describe the conversion of the insulin precursor to
human insulin of high purity by enzymatic and chemical
processing.
Results
Construction of the IP-secreting P. pastoris clone
The IP encoding gene, codon-optimized for expression in
P. pastoris, was obtained by chemical synthesis. The poly-
peptide encoded by this gene carries at the N-terminus 4
amino acids corresponding to the carboxy-terminal part
of the S. cerevisiae α-factor secretory signal (LEKR)
which contains the Kex2 cleavage site, followed by a
spacer peptide (EEAEAEAEPK) for more efficient Kex2
processing and secretion, followed by the insulin B chain
amino acids 1-29, a short connecting linker (AAK), and
finally the insulin A chain amino acids 1-21. This gene
was fused in-frame with the S. cerevisiae α-factor secre-
tory signal in the Pichia  integrative vector pPICZα to
generate the expression plasmid pPICZα-IP (Fig. 1). The
IP gene carries its own stop codon and, consequently,
does not contain the vector-encoded carboxy-terminal c-
myc and His6 tags. The IP secreted by this vector, follow-
ing Kex2 cleavage, is predicted to be 63 amino acids long
with a molecular mass of ~7 kDa. The plasmid pPICZα-
IP was linearized with SacI and electroporated into P.
pastoris  strain X-33 and the resulting transformants
selected on zeocin plates, containing progressively
increasing concentrations of zeocin (0.1 - 2.0 mg mL-1) to
identify multicopy clones. The maximum zeocin concen-
tration at which clones could be recovered was 0.5 mg
mL-1. Several clones that were viable at this zeocin con-
c e n t ra t io n w er e  t est ed i n s m al l sca le  induct io n e x pe ri-
ments. Extracellular IP concentrations were analyzed by
RP-HPLC to identify the best expressing clone. The
methanol utilization phenotype of this clone was found to
be Mut+, indicating that integration had occurred at the
AOX1 locus by a single crossover event.Gurramkonda et al. Microbial Cell Factories 2010, 9:31
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Production of IP in fed-batch culture
Initial attempts for secretory production of IP were based
on the direct application of the fed-batch procedure
recently developed for high-level intracellular production
of HBsAg with P. pastoris [35]. Employing these condi-
tions, cells were first grown in a batch procedure using a
simple defined medium with low salt and high glycerol
concentrations. After depletion of glycerol, induction of
product formation was achieved by adding methanol to a
final concentration of 6 g L-1 and keeping this high con-
centration for the remainder of the production phase.
This methanol concentration was very efficient for the
intracellular production of HBsAg leading only to minor
temporary growth arrest [35], however, these conditions
Table 1: Insulin precursor production with P. pastoris
Strain (copy#) MeOH
(%)
Induction time
(h)
Final biomass
(g L-1)
Product a
(g L-1)
Culture supernatant
Product b
(g L-1)
Culture broth
Mass Reference c
Mut+/s (6-8) nd d 87 nd 1.5 nd nd [26]
Muts (nd) 1.0 72 80 to 90 0.22 nd nd [25]
Muts (11) <0.1 110 89 0.3 nd MS e [24]
Muts (11) 1 to 0.5 136 109 0.25 nd MS [23]
Muts (nd) nd 72 nd 3.6 1.47 nd [27]
Mut+ (12) 0.8 96 nd 0.18 nd nd [28]
Mut+ (~2) f 0.2 88 59 3.84 3.075 MS Present study
a Concentrations were determined by reverse phase HPLC from clarified culture supernatant
b Concentrations calculated considering the volumetric portion of biomass in the culture broth
c Only references on secretory insulin precursor production with P. pastoris included containing respective quantitative data
d nd; not determined
e MS; mass spectrometry
f Copy number not experimentally determined. Survival at zeocin concentrations up to 0.5 mg mL-1 indicates a copy number of 2 [41].
Figure 1 Construction of the recombinant P. pastoris X-33 strain. (A) The IP gene and polypeptide sequence. The bent arrows indicate the ends 
of the IP gene and polypeptide. The tripeptide linking the B and A chains is underlined. The nucleotides comprising the 5' and 3' restriction sites are 
shown in italics. The A and B chain aa residue numbers carry the cognate 'A' and 'B' prefixes, respectively. The black triangles denote the sites of trypsin 
cleavage. (B) Map of the yeast integrative vector encoding IP. The IP is cloned between the XhoI site in the α-factor signal encoding sequence and the 
NotI site in the polylinker.
pPICZ -IP
B
Insulin Precursor
XhoI Spacer sequence
Leu Glu Lys Arg Glu Glu Ala Glu Ala Glu Ala Glu Pro Lys
CTC GAG AAG AGA GAA GAA GCT GAA GCT GAA GCT GAA CCA AAG
GAG CTC TTC TCT CTT CTT CGA CTT CGA CTT CGA CTT GGT TTC
B1  B2  B3  B4  B5  B6  B7  B8  B9  B10 B11 B12 B13 B14 B15
Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu
TTT GTT AAC CAA CAT TTG TGT GGT TCT CAT TTG GTT GAA GCT TTG
AAA CAA TTG GTT GTA AAC ACA CCA AGA GTA AAC CAA CTT CGA AAC
B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29
Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala Ala Lys
TAC TTG GTT TGT GGT GAA AGA GGT TTC TTC TAC ACT CCA AAG GCT GCT AAG
ATG AAC CAA ACA CCA CTT TCT CCA AAG AAG ATG TGA GGT TTC CGA CGA TTC
A1  A2  A3  A4  A5  A6  A7  A8  A9  A10 A11 A12 A13 A14 A15 A16
Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu
GGT ATT GTT GAA CAA TGT TGT ACT TCT ATT TGT TCT TTG TAC CAA TTC
CCA TAA CAA CTT GTT ACA ACA TGA AGA TAA ACA AGA AAC ATG GTT AAC
A17 A18 A19 A20 A21 END – 3’ NotI
Glu Asn Tyr Cys Asn
GAA AAC TAC TGT AAC TAA GCGGCCGC
A

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were detrimental for the secretory production of IP. In
this case, addition of methanol to final concentrations of
6 g L-1 was leading to a drastical drop of the optical den-
sity concomitant to foam formation indicative of pro-
found cell lysis (data not shown). Moreover, base
consumption was replaced by acid consumption indicat-
ing the formation and/or release of alkaline compounds.
Finally, cultivations had to be discontinued 10-15 h after
methanol addition due to uncontrollable foaming.
Thus, we aimed at less drastic conditions to induce the
secretory production of IP. After the depletion of glycerol
(Fig. 2A), methanol was first added to a final concentra-
tion of 1 g L-1 (Fig. 2B). With some time delay the cellular
adjustment to methanol utilization was noticeable by a
slight increase in the culture pH followed by acid addition
for culture pH maintenance (Fig. 2C) and a decrease in
the respiratory activity (Fig. 2D and 2E). Successful adap-
tation to methanol was then evident by the onset of
methanol consumption (Fig. 2B) and the increase of the
respiratory activity which started ~4 hours after metha-
nol addition (Fig. 2D and 2E). About 20 and 24 h after the
initial methanol pulse, the concentration of methanol in
the bioreactor was further increased to 1.5 and 2 g L-1,
respectively, and kept constant for the remainder of the
cultivation without causing noteworthy process pertuba-
tions, e.g. uncontrollable foaming (Fig. 2B). The biomass
concentration showed only a slight increase after the shift
to methanol, increasing from 56 to 59 g L-1 and starting to
decline again after about 120 h growth on methanol (Fig.
2A).
Recombinant IP production was analyzed by RP-HPLC
and SDS-PAGE during the induction phase from culture
aliquots withdrawn at various time points (Fig. 2F and 3,
respectively). Extracellular IP concentrations increased
during the first 80 h of growth on methanol reaching a
maximum of 3.075 gram per liter of culture broth. Taking
Figure 2 Two-phase fed-batch cultivation of P. pastoris X-33 carrying the AOX1 promoter-driven IP gene. Cells were first grown in a batch 
phase with glycerol as carbon source followed by a methanol feeding phase to induce the production of IP. (A) Concentrations of glycerol (filled 
squares) and biomass (optical density: filled circles; CDM: filled triangles). (B) Concentration of methanol (solid line) and amount of methanol added 
to the bioreactor (dashed line). (C) Medium pH (solid line), amount of ammonium hydroxide (dashed line), and amount of phosphoric acid added to 
the bioreactor (dotted line). (D) Dissolved oxygen concentration (solid line), aeration rate (dotted line), and stirrer speed (dashed line). (E) Oxygen trans-
fer (dashed line) and carbon dioxide evolution (solid line) rates and respiratory quotient (dotted line). Arrows indicate removal of culture broth. (F) Cell 
growth (filled circles) and accumulation of IP (filled squares). The dashed vertical line indicates the end of the glycerol batch and the start of the meth-
anol feeding phase.
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into account that the culture broth contained about 20%
(v/v) biomass and 80% (v/v) cell free culture supernatant,
the concentration of ~3 gram IP per liter culture broth
translates into almost 4 gram IP per liter culture superna-
tant. Absence of excessive foaming and equal high prod-
uct yields were also reached when the methanol
concentration was immediately increased to a final con-
centration of 2 g L-1 at the end of the glycerol batch phase
(data not shown). Degradation of IP was not observed
during the whole process. SDS-PAGE analysis of culture
supernatants revealed that IP accumulated as the most
prominent extracellular protein (Fig. 3).
Purification of IP from the culture broth
Two different purification procedures were employed for
the purification of IP from the culture broth. First, we
aimed at the separation of the insulin precursor from the
crude culture broth by using expanded bed absorption.
This procedure omits the clarification of the culture
broth by centrifugation and filtration, thus simplifying
the down-stream process. To allow binding of the insulin
precursor (theoretical pI  4.74) to the resin in the
expanded bed column, it was necessary to dilute and
acidify the culture broth. After loading and washing the
column in the expanded bed mode, the bound IP was
eluted in normal mode using 1 mol L-1 NaCl. The recov-
ery of IP was not satisfactory, however, it could be
increased two fold by supplementing the dilutent with the
detergent Tween 20, which allowed more efficient bind-
ing and elution of IP from the resin. Under optimized
conditions, ~1.5 g IP with a purity of 97% could be recov-
ered from one liter culture broth, using expanded bed
adsorption chromatography (Table 2).
Furthermore, we wanted to explore if the natural metal
binding affinities of human insulin and proinsulin [36-38]
could be exploited for an immobilized metal affinity
chromatography (IMAC) based purification step. Prelim-
inary tests revealed that the insulin precursor can bind to
IMAC columns precharged with Cu2+ and Ni2+ but - in
contrast to insulin - not to Zn2+-precharged columns.
Thus, the clarified culture broth was passed through Cu2+
pre-charged chelating sepharose fast flow (GE Health-
care) and, after extensive washing to remove unbound
impurities, the bound insulin precursor could be eluted at
Figure 3 Time course analysis of secretory IP production. Cell-free 
culture supernatants were analyzed by 10% Tricine SDS-PAGE from 
samples taken directly before the addition of methanol (time 0) and 24, 
48, 72, 96, 120 and 144 hours after the onset of methanol feeding. The 
arrow denotes the position of IP and M the lane of the molecular 
weight marker.
0   24    48   72    96  120  144    M           
Time of methanol feeding (hours)
250
150
100
75
50
37
25
20
15
10
kDa
Table 2: Purification of insulin precursor from microbial cultures
Expression host Chromatography matrix Recovery (%) a Purity (%) a Reference b
E. coli c IgG-Sepharose 90 nd d [10]
S. cerevisiae Streamline SP (XL)
Expanded bed adsorption
88 nd [43]
P. pastoris XAD-7T
Sephadex-G50
>80 e 60 e [26]
P. pastoris CM-Sepharose FF 97 97 [27]
P. pastoris Streamline SP (XL)
Expanded bed adsorption
55 97 Present study
P. pastoris IMAC-coupled with copper ions 95 96 Present study
a Recovery and purity relates to the first chromatographic step
b Only references on insulin precursor purification included containing respective quantitative data
c Insulin precursor fused to IgG binding domains produced in the form of inclusion bodies
d nd; not determined
e Recovery and purity relates to the two-step purification procedureGurramkonda et al. Microbial Cell Factories 2010, 9:31
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low pH. This step resulted in a recovery of 95% IP with a
purity of 96% (Table 2, Fig. 4A).
Conversion of IP to human insulin
The insulin precursor was transformed into pre-insulin
by enzymatic transpeptidation in the presence of trypsin
and O-t-butyl-L-threonine t-butyl ester (H-Thr(tBu)-
OtBu). During this reaction, the N-terminal spacer pep-
tide (EEAEAEAEPK) and the connecting linker peptide
(AAK) are removed (Fig. 1A) and the threonine ester is
added to B-29 in a transesterification reaction [33]. The
efficiency of this reaction is around 90%. There are three
species formed during the transpeptidation reaction
which can be detected by analytical RP-HPLC (Fig. 4B).
These species elute at retention times 21.8 min, 23.5 min,
and 29.1 min and correspond to B22 cleaved IP, B29
cleaved IP without the threonine ester, and the desired
reaction product pre-insulin-Thr(tBu)-OtBu (pre-insu-
lin), respectively. B22 cleaved IP and B29 cleaved IP with-
out the threonine ester represent only minor
contaminants, the majority of IP is transformed into pre-
insulin (Fig. 4B). Pre-insulin was purified from the trans-
esterification mixture using semi-preparative gradient
chromatography (Resource RPC column, Table 3).
The final recombinant human insulin was obtained
from pre-insulin by removal of the blocking tertiary butyl
groups from threonine in position B30 by acidolysis with
trifluoroacetic acid (deprotection reaction). This step was
tested at different temperatures (RT, ice, 10°C) and incu-
bation times (from 30 min to 4 h). The highest yields were
reached at RT with a reaction time of 60 min. After 60
min, more than 90% of pre-insulin is converted to human
insulin (Fig. 4D). Only a minor fraction (~2%) of pre-
insulin is converted into undesired by-products such as
A21 desamido insulin. Finally, recombinant human insu-
lin was purified by RP-HPLC as described in the Materi-
Figure 4 RP-HPLC profiles of insulin species recovered after IMAC, transpeptidation and deprotection reactions, and final purification. (A) 
RP-HPLC profile of the purified IP from IMAC. IP was eluted at a retention time of 19.4 minutes. (B) RP-HPLC profile of insulin species recovered after 
the transpeptidation reaction with i) pre-insulin H-Thr(tBu)-OtBu; ii) insulin species cleaved at B29 without the threonine ester; and iii) Insulin species 
cleaved at B22. (C) RP-HPLC profile of deprotection reaction in which the pre-insulin reaction mixture was incubated at room temperature for 5 min-
utes, with i) pre-insulin H-Thr(tBu)-OtBu; iv) insulin Thr-OtBu; and v) human insulin. (D) RP-HPLC profile of deprotection reaction in which the pre-in-
sulin reaction mixture was incubated at room temperature for 60 minutes (E) RP-HPLC profile of purified human insulin. (F) RP-HPLC profile of mixture 
of human insulin and European Pharmacopoeia human insulin standard. The Phenomenex Jupiter C4 column was employed for quantification of in-
sulin species. The identity of insulin species was determined by mass spectrometry as specified in the Materials and Methods section.
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als and Methods section. During this step, the A21
desamido insulin and other impurities are removed rais-
ing the purity of human insulin to 99% as determined by
RP-HPLC (Fig. 4E) fully satisfying the European Pharma-
copoeia requirements [39]. The total yield of the
described process is around 60% (Table 3).
Discussion
Production of recombinant proteins can be stressful to
the host organism [40]. Compared to the intracellular
production of HBsAg [35], the secretory production of IP
is more harmful to the cells. Using high methanol con-
centrations for induction, extensive cell lysis is observed
in the case of extracellular IP production but not in the
case of the intracellular production of HBsAg. Although
the extent of the cellular stress response is influenced by
the nature of the recombinant product, membrane dam-
age associated cell lysis is more likely to occur when the
recombinant protein is directed towards the extracellular
environment compared to intracellular product reten-
tion. In case of secretory protein production, less harsh
induction conditions might be more advantageous to
reduce growth perturbations to acceptable levels while
keeping production levels high. For secretory IP produc-
tion with P. pastoris, induction at a final methanol con-
centration of 2 g L-1  is appropriate for high level
production. This methanol concentration does not cause
cell lysis and only leads to a neglectable increase in bio-
mass during the production phase, thus, leading to opti-
mal conditions for the recovery of proteins from the
extracellular environment.
In conclusion, a simple two-phase cultivation process
composed of a glycerol batch and a constant methanol
fed-batch phase was adapted to secretory IP production.
This approach increases IP levels more than 2 times com-
pared to the highest previously reported value using
Pichia based expression systems. Moreover, we propose a
novel procedure to capture the insulin precursor from the
culture supernatant using IMAC and, finally, show that
~1.5 g of 99% pure recombinant human insulin can be
obtained per liter of culture broth.
Materials and methods
Strains and vectors
P. pastoris host strain X-33 and the plasmid vector
pPICZα were purchased from Invitrogen. Plasmid
pPICZα (Invitrogen Cat. No. V195-20) was used to con-
struct the methanol inducible IP expression vector. A
synthetic codon-optimized gene encoding the IP was
inserted into the polylinker of this vector, in-frame with
the α-factor secretion signal sequence to create the
expression plasmid pPICZα-IP, which was then inte-
grated into the genome of P. pastoris strain X-33. Trans-
formation of Pichia, selection and screening of
transformants to identify clones harboring the IP inserts,
the isolation of putative multicopy clones using the zeo-
Table 3: Purification of insulin precursor by IMAC and conversion to human insulin
Steps Insulin species
(molecular mass)
Amount (mg) a Amount (mmol) a Recovery (%) a Purity (%) a
Culture broth b Insulin precursor
7041 Da
3075 0.437 100 20
Chelating sepharose FF c Insulin precursor
7041 Da
2921 0.415 95 96
Desalting & Lyophilization Insulin precursor
7041 Da
2859 0.406 93 98
Transpeptidation Pre-insulin
5920 Da
n.d. d n.d. d n.d. d n.d. d
Resource RPC Desalting & 
Lyophilization
Pre-insulin
5920 Da
1915 0.323 74 90
Deprotection Human insulin
5808 Da
n.d. d n.d. d n.d. d n.d. d
Resource RPC (two 
passages), Desalting & 
Lyophilization
Human insulin
5808 Da
1537 0.264 60 99
a Recovery and purity was determined by RP-HPLC
b 200 mg of IP were used for further processing. Data extrapolated to 1-L culture broth
c Centrifugation step included before chromatography
d n.d., not determinedGurramkonda et al. Microbial Cell Factories 2010, 9:31
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cin screening protocol, and the identification of the
methanol utilization (mut) phenotype were performed
essentially as described previously [41].
Culture conditions, control and on-line measurements
Precultures for high-cell density bioreactor cultivations
were prepared as described before [35]. High-cell density
cultivations were carried out in a 15-L BIOSTAT-C (B.
Braun Biotech International, Germany) bioreactor essen-
tially as described previously [35] with minor modifica-
tions. A 1-L preculture was transferred to the bioreactor
containing 7 L growth medium. The growth medium
contained per liter: glycerol, 95.2 g; potassium di-hydro-
gen phosphate, 9.4 g; yeast trace metal (YTM) solution,
4.56 g; ammonium sulfate, 15.7 g; magnesium sulfate
hepta-hydrate, 4.6 g; calcium chloride di-hydrate, 0.28 g;
and biotin, 0.4 mg. The YTM solution contained: potas-
sium iodide, 207.5 mg L-1; manganese sulfate, 760.6 mg L-
1; di-sodium molybdate, 484 mg L-1; boric acid, 46.3 mg L-
1; zinc sulfate hepta-hydrate, 5.032 g L-1; ferric chloride
hexa-hydrate, 12.0 g L-1; and sulfuric acid, 9.2 g L-1.
Foaming was controlled by the addition of antifoam
(Ucolub N115). Temperature was maintained at 30°C and
pH at pH 5.5 with 12.5% (v/v) NH4OH or 1 mol L-1
H3PO4. Aeration rate was maintained at 4 L min-1
throughout the process. The stirrer speed was controlled
between 100 to 1370 rpm aiming at a dissolved oxygen
(DO) concentration of 20% air saturation. After con-
sumption of glycerol, indicated by an increase of the DO
concentration, production of recombinant IP was initi-
ated by step-wise addition of a methanol solution [96.6%
(w/w) methanol and 4.4% (w/w) YTM] to a final metha-
nol concentration of 2 g L-1, which was maintained con-
stant throughout the remainder of the induction period
based on on-line  measured methanol concentrations
determined from the methanol vapor in the off-gas using
a flame ionization detector (Ratfish Instruments, Ger-
many). Based on the gas liquid phase equilibrium metha-
nol concentrations were determined in the off-gas using
two point calibrations directly before and after induction.
The concentrations of oxygen and carbon dioxide in the
exhaust gas were determined by paramagnetic and infra-
red exhaust gas analysis systems, respectively (Maihak,
Hamburg, Germany).
Determination of cell concentration
The cell concentration of suitably diluted culture samples
was measured by optical density (OD) at 600 nm using a
Novaspec II spectrophotometer (Pharmacia LKB). For
cell dry mass (CDM) determination, 1-mL aliquots of the
culture broth were pelleted (13,000 rpm for 15 min at
room temperature using an Eppendorf microcentrifuge,
model 5415C) in pre-weighed tubes, re-suspended in 50
mmol L-1 phosphate buffer (pH 7.2), re-centrifuged and
the resultant pellets vacuum-dried at 80°C (Heraeus
Instruments, Vacutherm) to constant mass. CDM was
measured in triplicates and averaged.
Determination of glycerol concentration
Culture samples (1-mL) were centrifuged (13,000 rpm for
15 min at 4°C) and the glycerol concentration in the
supernatant analyzed in duplicate using glycerol test kits
(Roche, Basel, Switzerland).
Protein analysis
Clarified culture broth samples were analyzed by dena-
turing 10%-polyacrylamide gel electrophoresis using the
Tricine buffer system [42]. Samples (40-μL) were mixed
with an equal volume of loading buffer [250 mmol L-1 Tri-
cine (pH 8.5), 10% β-mercaptoethanol, 2% SDS, 1% glyc-
erol, and 0.1% bromophenol blue], vortexed for 1 min and
boiled for 15 min, vortexed again, clarified by centrifuga-
tion (max speed, 15 min, RT) and loaded on the gel (20 μL
per lane). Following electrophoresis, the separated poly-
peptides were visualized using Coomassie blue staining.
Reversed-phase HPLC (RP-HPLC) was used for quanti-
fication of IP from culture broth. Filtered aliquots of
Pichia culture broth (200-μL) were mixed with an equal
volume of solution A [0.15% (v/v) TFA in MilliQ water]
and analyzed by RP-HPLC using a 3 μm SUPELCOSIL™
LC-304 column (3.3 cm × 4.6 mm) with a Schimadzu liq-
uid chromatography system, equipped with an auto-
injector (SIL-10AD VP), UV-VIS detector (SPD-10A),
pumps A and B (LC-10AT VP), and a controller (SCL-
10A  VP). The HPLC column was maintained at 24°C
(HPLC column oven, CH-500, Eppendorf, Germany).
Elution was done with a gradient formed by mixing solu-
tions A and B [0.15% (v/v) TFA in acetonitrile] as follows:
10% B (0 - 6 min), 10 - 43% B (6 - 41 min), 43 - 100% B (41
- 43 min), 100 - 10% B (43 - 53 min), 10% B (53 - 60 min).
The flow rate was maintained at 1 mL min-1. The column
effluent was monitored at 280 nm.
Reversed-phase HPLC (RP-HPLC) was also used for
characterization and quantification of IP and insulin spe-
cies after purifications, transpeptidation, and deprotec-
tion. These samples were loaded on a 5 μm Phenomenex
Jupiter C4 column (300A, 250 mm × 4.6 mm) in solution
A [0.1% (v/v) TFA in MilliQ water]. Elution was done at
25°C with a gradient formed by mixing solutions A and B
[0.1% (v/v) TFA in acetonitrile] as follows: 0 - 20% B (0 - 6
min), 20 - 55% B (6 - 41 min), 55 - 100% B (41 - 42 min).
The flow rate was also 1 mL min-1 and the column efflu-
ent was monitored at 280 nm.
Purification of IP using expanded bed absorption
The culture broth (1-L) was diluted with 4 liter of 1%
Tween 20 (pH 2.0, 4.7 mS cm-1) to reduce the salt content
(conductivity of culture broth was 24.2 mS cm-1), the pH
and the viscosity for more efficient binding to the Stream-Gurramkonda et al. Microbial Cell Factories 2010, 9:31
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line SP XL resin (Amersham Pharmacia Biotech, Swe-
den). A Streamline 50 column (Amersham Pharmacia
Biotech, Sweden) packed with Streamline SP XL resin to
a sedimented height of 13 cm and pre-equilibrated with
1% Tween 20 (pH 2.0; 4.7 mS cm-1) was employed and the
diluted and well mixed culture broth was pumped from
the lower end of the column leading to an expansion of
the sedimented height to 24.4 cm (H/Ho expansion ratio =
1.88, where H and Ho represent the heights of the column
bed after and before expansion, respectively). After load-
ing, the column was washed with MilliQ water (pH 5.8)
until the absorbance at 280 nm returned to base line in
the eluate. Following, the bound IP was eluted using con-
ventional chromatography by reversing the flow in a now
settled bed using 1 mol L-1 NaCl (pH 7.5, conductivity
~100 mS cm-1). Protein containing fractions (absorbance
at 280 nm) were pooled and loaded on a preparative C18
bulk column (125 A0 55-105 μm, Waters Corporation,
M i l f o r d ,  M A ,  U S A )  p r e - e q u i l i b r a t e d  w i t h  1 0 %  a c e -
tonitrile and 0.1% TFA. After loading, the column was
washed with 10% acetonitrile and 0.1% TFA and elution
was carried out with 60% acetonitrile and 0.1% TFA. The
eluted protein was lyophilized prior to further treatment
(Labconco freeze dry system, Germany).
Purification of IP using íon metal affinity chromatography
The culture broth (1-L) was centrifuged (Sorvall
RC5BPlus centrifuge, SLA 3000 rotor) at 4°C and 3,000
rpm for 30 min. The supernatant was filtered using a 0.22
μm filter, the pH adjusted to pH 7.0 and the clarified cul-
ture supernatant allowed to bind to Cu2+ pre-charged
chelating sepharose fast flow (GE Healthcare) pre-equili-
brated in equilibration buffer [20 mmol L-1 sodium phos-
phate buffer (pH 7.0), 500 mmol L-1  NaCl] at room
temperature. A maximum of 200 mg IP was used per 50
mL column volume. After sample loading, the column
was extensively washed with equilibration buffer to
remove unbound proteins. The bound IP was eluted by a
linear pH gradient using a low pH elution buffer [20
mmol L-1 sodium phosphate buffer (pH 3.15), 500 mmol
L-1 NaCl]. The purified IP was diluted with MilliQ water
to lower the conductivity to appr. 8 mS cm-1 and the pH
adjusted to pH 4.0 to allow binding to HiTrap SP HP col-
umn (GE Healthcare). Elution was performed using 100
mmol L-1 NH4HCO3 (pH 9.0). The purified IP was lyo-
philized prior to the conversion to pre-insulin by trans-
peptidation.
Transpeptidation, deprotection and final purification of 
human insulin
The transpeptidation reaction was essentially performed
as described previously [33] with minor modifications.
Briefly, the reaction mixture contained 10 mmol L-1 insu-
lin precursor, 200 μmol L-1  trypsin, 0.8 mol L-1  H-
Thr(tBu)-OtBu, 7 mmol L-1 CaCl2, 50% dimethylforma-
mide/ethanol 1:1 (v/v) and 26% water with the pH
adjusted to pH 6.0 with acetic acid. The reaction was car-
ried out at 12°C for 24 hrs. The reaction mixture was sub-
jected to semi-preparative gradient chromatography for
purification of pre-insulin using a Resource RPC column
(GE Healthcare). The bound pre-insulin was eluted by a
gradient formed by mixing solutions A (0.2 mol L-1
ammonium sulphate buffer, pH 2.0) and B (0.1 mol L-1
ammonium sulphate buffer with 40% (v/v) acetonitrile) as
follows: 0 - 45% B (16.6 column volumes, CV), 45% B
(16.6 CV), 45 - 75% B (16.6 CV), 75% B (2.7 CV), 75 -
100% B (3 CV). The purified pre-insulin was desalted by
cation exchange chromatography (HiTrap SP HP column,
GE Healthcare, elution with 100 mmol L-1 NH4HCO3, pH
9) and lyophilized prior to further processing.
Pre-insulin was transformed to human insulin by
removal of the tertiary-butyl groups of threonine in posi-
tion B30 by acidolysis using trifluoroacetic acid (19 μL
TFA per mg pre-insulin). To protect the polypeptide from
degradation and desamidation, 0.05 mg each of L-trypto-
phan and L-glutamine per mg pre-insulin were included
as scavengers in the reaction mixture which also con-
tained 2.5% water.
Final purification of human insulin was carried out by
semi-preparative gradient chromatography (Resource
RPC column, GE Healthcare). The deprotection reaction
mixture was subjected to gradient chromatography by
mixing solutions A [90% ammonium acetate buffer (1
mol L-1, pH 7.0) and 10% acetonitrile] and B [50% ammo-
nium acetate buffer (1 mol L-1, pH 7.0) and 50% ace-
tonitrile] as follows: 0 - 35% B (1 CV), 35% B (26.6 CV),
35 - 50% B (6 CV), 50% B (6 CV), 50 - 100% B (4 CV). The
eluted recombinant human insulin was desalted and lyo-
philized as described above for long term storage.
Mass spectrometry
Electrospray mass spectrometry (ESI-MS) was performed
with API 150EX, PE SCIEX instrument (Applied Biosys-
tems). Samples eluted from Resource RPC columns were
desalted (HiTrap SP HP column, GE Healthcare) and lyo-
philized. Lyophilized samples were reconstituted in 0.1%
TFA and 80% acetonitrile in MilliQ water and analyzed
by direct infusion (5 μL min-1) in the interval of 600-2500
m/z. Spectra were acquired using LC2Tune 1.4 Software
and the molecular mass was obtained by automatic
deconvolution using the Biomultiview software.
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